Microbot Medical (MBOT) presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center, Baptist Hospital of Miami and Brigham and Women’s Hospital (Boston, MA). The late-breaking podium presentation was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering Cancer Center. The data presented concluded that robotic endovascular procedures using LIBERTY(R) are feasible and significantly minimize radiation exposure. Significant Highlights of the ACCESS-PVI Study: Successful robotic navigation was achieved in every case, yielding a success rate of 100%, meeting the primary endpoint of the study. No Adverse Device Events were reported through the duration of follow-up. Mean difference in radiation exposure between operator and control was (-)29.8 microS, resulting in a mean 92% relative reduction in radiation exposure. Median robotic navigation time to target was 3 minutes. Participating physicians reported LIBERTY(R) performed as planned with a 100% satisfaction rate.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT: